Last reviewed · How we verify
Opdivo Injectable Product — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Opdivo Injectable Product (Opdivo Injectable Product) — Rampart Health, L.L.C..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Opdivo Injectable Product TARGET | Opdivo Injectable Product | Rampart Health, L.L.C. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Opdivo Injectable Product CI watch — RSS
- Opdivo Injectable Product CI watch — Atom
- Opdivo Injectable Product CI watch — JSON
- Opdivo Injectable Product alone — RSS
Cite this brief
Drug Landscape (2026). Opdivo Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/opdivo-injectable-product. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab